Rafferty Asset Management LLC Sells 42,906 Shares of MiMedx Group, Inc. (NASDAQ:MDXG)

Rafferty Asset Management LLC lowered its position in shares of MiMedx Group, Inc. (NASDAQ:MDXGFree Report) by 19.1% in the 4th quarter, Holdings Channel.com reports. The fund owned 181,694 shares of the company’s stock after selling 42,906 shares during the quarter. Rafferty Asset Management LLC’s holdings in MiMedx Group were worth $1,593,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Victory Capital Management Inc. increased its position in shares of MiMedx Group by 23.1% during the fourth quarter. Victory Capital Management Inc. now owns 14,916 shares of the company’s stock valued at $131,000 after acquiring an additional 2,796 shares in the last quarter. AJOVista LLC bought a new stake in shares of MiMedx Group during the fourth quarter valued at approximately $25,000. New York State Common Retirement Fund boosted its holdings in MiMedx Group by 6.9% in the fourth quarter. New York State Common Retirement Fund now owns 49,419 shares of the company’s stock worth $433,000 after purchasing an additional 3,204 shares during the last quarter. DekaBank Deutsche Girozentrale purchased a new stake in MiMedx Group in the third quarter worth approximately $38,000. Finally, Jump Financial LLC boosted its holdings in MiMedx Group by 8.7% in the fourth quarter. Jump Financial LLC now owns 97,260 shares of the company’s stock worth $853,000 after purchasing an additional 7,753 shares during the last quarter. Institutional investors own 79.15% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. Lake Street Capital assumed coverage on shares of MiMedx Group in a report on Thursday, March 7th. They issued a “buy” rating and a $12.00 target price on the stock. HC Wainwright restated a “buy” rating and issued a $11.00 target price on shares of MiMedx Group in a report on Wednesday, May 1st. Mizuho raised their target price on shares of MiMedx Group from $13.00 to $14.00 and gave the stock a “buy” rating in a report on Friday, March 1st. Finally, StockNews.com upgraded shares of MiMedx Group from a “buy” rating to a “strong-buy” rating in a report on Monday, June 3rd. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, MiMedx Group has an average rating of “Buy” and an average target price of $12.25.

Get Our Latest Report on MDXG

Insider Transactions at MiMedx Group

In other news, CAO William Frank Iv Hulse sold 20,381 shares of MiMedx Group stock in a transaction on Wednesday, March 13th. The shares were sold at an average price of $7.95, for a total transaction of $162,028.95. Following the transaction, the chief accounting officer now owns 479,959 shares in the company, valued at approximately $3,815,674.05. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 1.30% of the company’s stock.

MiMedx Group Trading Down 0.6 %

Shares of MiMedx Group stock opened at $6.99 on Tuesday. The company’s fifty day simple moving average is $7.08 and its 200-day simple moving average is $7.76. The stock has a market capitalization of $1.03 billion, a PE ratio of 15.89 and a beta of 1.91. MiMedx Group, Inc. has a 1-year low of $5.51 and a 1-year high of $9.27. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.29 and a quick ratio of 2.71.

MiMedx Group (NASDAQ:MDXGGet Free Report) last issued its quarterly earnings results on Tuesday, April 30th. The company reported $0.07 earnings per share for the quarter, topping the consensus estimate of $0.04 by $0.03. The business had revenue of $84.71 million for the quarter, compared to analysts’ expectations of $79.36 million. MiMedx Group had a net margin of 18.63% and a return on equity of 39.42%. As a group, equities analysts anticipate that MiMedx Group, Inc. will post 0.34 earnings per share for the current year.

MiMedx Group Company Profile

(Free Report)

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.

Featured Stories

Want to see what other hedge funds are holding MDXG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MiMedx Group, Inc. (NASDAQ:MDXGFree Report).

Institutional Ownership by Quarter for MiMedx Group (NASDAQ:MDXG)

Receive News & Ratings for MiMedx Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiMedx Group and related companies with MarketBeat.com's FREE daily email newsletter.